Shares of cancer diagnostics company Precipio, Inc. PRPO have soared 170% this week after the company said it launched a COVID-19 test on the Amazon.com, Inc. AMZN business platform.
A similar thing happened in July when Precipio first announced its COVID-19 strategy. Shares made an even larger move than they did this week.
Investors should focus on two key levels.
In July, shares reached $8, but by the close, they backed off to $7. Levels that had previously been resistance can become resistance again. If PRPO reaches these levels, there is a good chance the rally stalls out at them once more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
